Targeting RAD51-Mediated Homologous Recombination as a Treatment for Advanced Solid and Hematologic Malignancies: Opportunities and Challenges Ahead.
Saved in:
| Title: | Targeting RAD51-Mediated Homologous Recombination as a Treatment for Advanced Solid and Hematologic Malignancies: Opportunities and Challenges Ahead. |
|---|---|
| Authors: | Tsang ES; Division of Hematology and Oncology, University of California San Francisco, San Francisco, CA, 94158, USA., Munster PN; Division of Hematology and Oncology, University of California San Francisco, San Francisco, CA, 94158, USA. |
| Source: | OncoTargets and therapy [Onco Targets Ther] 2022 Dec 13; Vol. 15, pp. 1509-1518. Date of Electronic Publication: 2022 Dec 13 (Print Publication: 2022). |
| Publication Type: | Journal Article; Review |
| Journal Info: | Publisher: Dove Medical Press Country of Publication: New Zealand NLM ID: 101514322 Publication Model: eCollection Cited Medium: Print ISSN: 1178-6930 (Print) Linking ISSN: 11786930 NLM ISO Abbreviation: Onco Targets Ther Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
